Title : An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.

Pub. Date : 2021 Feb

PMID : 33273056






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 An anti-CD22-seco-CBI-Dimer ADC for the treatment of non-Hodgkin lymphoma that provides a longer duration of response than auristatin ADCs in preclinical models. auristatin CD22 molecule Homo sapiens